Revance Therapeutics Inc. (RVNC) 22.31 $RVNC
TherapeuticsMD Appoints Biopharmaceutical Senior Executives Angus C. Russell and J. Martin Carroll as Independent Directors
Business Wire - Wed Mar 18, 7:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, announced today the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors.
TXMD: 7.17 (+0.01), SHPG: 253.58 (+3.70), RVNC: 22.31 (-0.58)
4 Stocks Spiking on Big Volume: Arista Networks and More
at The Street - Mon Mar 16, 11:52AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
ANET: 66.27 (+0.40), CTSO: 7.13 (-0.06), RVNC: 22.31 (-0.58), HSIC: 141.11 (+1.14)
Revance Therapeutics' (RVNC) CEO Dan Browne on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:40PM CST
RVNC: 22.31 (-0.58)
Revance reports 4Q loss
Automated Insights - Mon Mar 02, 5:13PM CST
NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $14.2 million in its fourth quarter.
RVNC: 22.31 (-0.58)
Revance Therapeutics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:22PM CST
RVNC: 22.31 (-0.58)
Revance Therapeutics Releases Fourth Quarter and Full Year 2014 Financial Results and Reiterates 2015 Outlook
GlobeNewswire - Mon Mar 02, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today financial results for the fourth quarter and full year ended December 31, 2014.
RVNC: 22.31 (-0.58)
Revance Therapeutics, Inc. Announces Participation in Cowen 35th Annual Health Care Conference
GlobeNewswire - Tue Feb 17, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen and Company 35th Annual Health Care Conference in Boston.
RVNC: 22.31 (-0.58)
Revance Therapeutics to Release Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, March 2, 2015
GlobeNewswire - Thu Feb 12, 3:09PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that the Company will release fourth quarter and full year 2014 financial results on Monday, March 2, 2015 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.
RVNC: 22.31 (-0.58)
Commit To Purchase Revance Therapeutics At $15, Earn 13.2% Annualized Using Options
at The Street - Fri Jan 23, 11:02AM CST
Investors eyeing a purchase of Revance Therapeutics Inc stock, but cautious about paying the going market price of $16.86/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
RVNC: 22.31 (-0.58)
Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015
GlobeNewswire - Mon Jan 12, 6:00AM CST
Specifies Milestones for Botulinum Toxin Product Candidates, Topical RT001 and Injectable RT002, for Aesthetic and Therapeutic Indications
RVNC: 22.31 (-0.58)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 4:35PM CST
HELE: 79.26 (-0.19), EOPN: 8.59 (unch), RRTS: 25.07 (-0.25), CNAT: 6.31 (-0.15), JNUG: 19.83 (-2.03), RVNC: 22.31 (-0.58), AGI: 6.74 (-0.39), FIVE: 35.27 (-0.01), BARL: 19.19 (unch), SBLK: 3.67 (-0.11)
Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study
GlobeNewswire - Thu Jan 08, 3:06PM CST
RT002 Achieved Median Duration of 7 Months
RVNC: 22.31 (-0.58)
Revance starts Phase 2 trial for aesthetic treatment for frown lines
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:40AM CST
RVNC: 22.31 (-0.58)
Revance Therapeutics Announces Initiation of BELMONT Phase 2 Active Comparator Trial of Injectable RT002
GlobeNewswire - Mon Jan 05, 6:23AM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, today announced initiation of the BELMONT trial, a Phase 2, Randomized, Double-Blind, DosE Ranging, Active and PLacebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration Of Effect of RT002, a BotuliNum Toxin Type A for Injection, to Treat Glabellar Lines, more commonly known as frown lines. RT002, incorporating Revance's patented TransMTS(R) delivery technology, is an investigational product designed to offer more targeted delivery of botulinum toxin to intended treatment sites with reduced spread beyond the site of local injection. Last April, Revance reported the results of a Phase1/2 study which showed median duration of 29.4 weeks, which exceeds the labeled duration of currently marketed botulinum toxin products for the treatment of glabellar lines.
RVNC: 22.31 (-0.58)
Revance Therapeutics Added to NASDAQ Biotechnology Index
GlobeNewswire - Thu Dec 18, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:^NBI), which will become effective upon market open on Monday, December 22, 2014.
IBB: 363.84 (-0.66), RVNC: 22.31 (-0.58)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 39.96 (-0.50), ZSPH: 42.50 (+1.08), AMRN: 2.34 (-0.05), OPHT: 52.35 (+1.09), AERI: 34.42 (-0.70), ASPX: 100.79 (+0.09), CNCE: 14.83 (+0.26), ICEL: 16.47 (-0.02), GWPH: 113.04 (-0.05), AUXL: 36.47 (-0.06), RTRX: 24.45 (+0.09), RCPT: 166.76 (-3.37), AAVL: 38.93 (-0.42), AKBA: 8.39 (+0.07), EXPR: 17.33 (+0.04), RARE: 66.96 (+2.74), RLYP: 35.39 (-0.54), PETX: 16.15 (+0.01), ENTA: 36.99 (+0.01), RDUS: 41.90 (-0.48), CARA: 12.98 (+0.15), FLML: 15.84 (-0.33), ALIM: 4.92 (-0.09), ANIP: 69.79 (+1.24), ICPT: 280.45 (-8.26), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22), FPRX: 24.07 (-0.85), ZFGN: 39.06 (+0.36), CRIS: 2.88 (+0.09), QLTI: 3.75 (-0.04), PCYC: 256.98 (-0.77), PTX: 7.44 (-0.05), CLDN: 13.59 (-2.77), RIGL: 4.24 (+0.07), HPTX: 45.96 (-0.18), AMPH: 15.08 (-0.13), INO: 10.39 (-0.09), VSAR: 18.31 (-0.81), FMI: 48.71 (-0.96), TBPH: 18.41 (+0.18), XLRN: 33.67 (-0.02), MGNX: 33.73 (-0.05), INSM: 23.12 (-0.10), ONTX: 2.48 (-0.05), ALDR: 25.13 (-0.19), SAGE: 59.50 (-2.56), KITE: 57.56 (-1.43), CGEN: 7.10 (+0.01), FOLD: 11.97 (-0.35), KPTI: 32.24 (-0.60)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 39.96 (-0.50), ZSPH: 42.50 (+1.08), AMRN: 2.34 (-0.05), OPHT: 52.35 (+1.09), AERI: 34.42 (-0.70), ASPX: 100.79 (+0.09), CNCE: 14.83 (+0.26), ICEL: 16.47 (-0.02), GWPH: 113.04 (-0.05), AUXL: 36.47 (-0.06), RTRX: 24.45 (+0.09), RCPT: 166.76 (-3.37), AAVL: 38.93 (-0.42), AKBA: 8.39 (+0.07), EXPR: 17.33 (+0.04), RARE: 66.96 (+2.74), ZGNX: 1.63 (-0.02), RLYP: 35.39 (-0.54), PETX: 16.15 (+0.01), ENTA: 36.99 (+0.01), RDUS: 41.90 (-0.48), CARA: 12.98 (+0.15), FLML: 15.84 (-0.33), ALIM: 4.92 (-0.09), ANIP: 69.79 (+1.24), ICPT: 280.45 (-8.26), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22), NDAQ: 48.84 (+0.12), FPRX: 24.07 (-0.85), CRIS: 2.88 (+0.09), ZFGN: 39.06 (+0.36), QLTI: 3.75 (-0.04), PCYC: 256.98 (-0.77), PTX: 7.44 (-0.05), CLDN: 13.59 (-2.77), RIGL: 4.24 (+0.07), HPTX: 45.96 (-0.18), AMPH: 15.08 (-0.13), INO: 10.39 (-0.09), VSAR: 18.31 (-0.81), FMI: 48.71 (-0.96), TBPH: 18.41 (+0.18), XLRN: 33.67 (-0.02), MGNX: 33.73 (-0.05), INSM: 23.12 (-0.10), ONTX: 2.48 (-0.05), ALDR: 25.13 (-0.19), SAGE: 59.50 (-2.56), KITE: 57.56 (-1.43), CGEN: 7.10 (+0.01), FOLD: 11.97 (-0.35), KPTI: 32.24 (-0.60)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), NKTR: 10.90 (+0.16), AGN: 240.22 (+2.88), IPXL: 49.58 (-0.40), ALDR: 25.13 (-0.19), MRK: 57.69 (+0.03), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 100.43 (+0.13), RVNC: 22.31 (-0.58), CLTX: 0.74 (-0.01), GSK: 46.57 (-0.67), NKTR: 10.90 (+0.16), NVS: 103.45 (-0.62)
Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Thu Nov 20, 6:20PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the 26 Annual Piper Jaffray Healthcare Conference.
RVNC: 22.31 (-0.58)
TherapeuticsMD Appoints Biopharmaceutical Senior Executives Angus C. Russell and J. Martin Carroll as Independent Directors
Business Wire - Wed Mar 18, 7:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, announced today the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors.
TXMD: 7.17 (+0.01), SHPG: 253.58 (+3.70), RVNC: 22.31 (-0.58)
4 Stocks Spiking on Big Volume: Arista Networks and More
at The Street - Mon Mar 16, 11:52AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
ANET: 66.27 (+0.40), CTSO: 7.13 (-0.06), RVNC: 22.31 (-0.58), HSIC: 141.11 (+1.14)
Revance Therapeutics' (RVNC) CEO Dan Browne on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:40PM CST
RVNC: 22.31 (-0.58)
Revance reports 4Q loss
Automated Insights - Mon Mar 02, 5:13PM CST
NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $14.2 million in its fourth quarter.
RVNC: 22.31 (-0.58)
Revance Therapeutics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:22PM CST
RVNC: 22.31 (-0.58)
Revance Therapeutics Releases Fourth Quarter and Full Year 2014 Financial Results and Reiterates 2015 Outlook
GlobeNewswire - Mon Mar 02, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today financial results for the fourth quarter and full year ended December 31, 2014.
RVNC: 22.31 (-0.58)
Revance Therapeutics, Inc. Announces Participation in Cowen 35th Annual Health Care Conference
GlobeNewswire - Tue Feb 17, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen and Company 35th Annual Health Care Conference in Boston.
RVNC: 22.31 (-0.58)
Revance Therapeutics to Release Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, March 2, 2015
GlobeNewswire - Thu Feb 12, 3:09PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that the Company will release fourth quarter and full year 2014 financial results on Monday, March 2, 2015 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.
RVNC: 22.31 (-0.58)
Commit To Purchase Revance Therapeutics At $15, Earn 13.2% Annualized Using Options
at The Street - Fri Jan 23, 11:02AM CST
Investors eyeing a purchase of Revance Therapeutics Inc stock, but cautious about paying the going market price of $16.86/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
RVNC: 22.31 (-0.58)
Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015
GlobeNewswire - Mon Jan 12, 6:00AM CST
Specifies Milestones for Botulinum Toxin Product Candidates, Topical RT001 and Injectable RT002, for Aesthetic and Therapeutic Indications
RVNC: 22.31 (-0.58)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 4:35PM CST
HELE: 79.26 (-0.19), EOPN: 8.59 (unch), RRTS: 25.07 (-0.25), CNAT: 6.31 (-0.15), JNUG: 19.83 (-2.03), RVNC: 22.31 (-0.58), AGI: 6.74 (-0.39), FIVE: 35.27 (-0.01), BARL: 19.19 (unch), SBLK: 3.67 (-0.11)
Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study
GlobeNewswire - Thu Jan 08, 3:06PM CST
RT002 Achieved Median Duration of 7 Months
RVNC: 22.31 (-0.58)
Revance starts Phase 2 trial for aesthetic treatment for frown lines
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:40AM CST
RVNC: 22.31 (-0.58)
Revance Therapeutics Announces Initiation of BELMONT Phase 2 Active Comparator Trial of Injectable RT002
GlobeNewswire - Mon Jan 05, 6:23AM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, today announced initiation of the BELMONT trial, a Phase 2, Randomized, Double-Blind, DosE Ranging, Active and PLacebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration Of Effect of RT002, a BotuliNum Toxin Type A for Injection, to Treat Glabellar Lines, more commonly known as frown lines. RT002, incorporating Revance's patented TransMTS(R) delivery technology, is an investigational product designed to offer more targeted delivery of botulinum toxin to intended treatment sites with reduced spread beyond the site of local injection. Last April, Revance reported the results of a Phase1/2 study which showed median duration of 29.4 weeks, which exceeds the labeled duration of currently marketed botulinum toxin products for the treatment of glabellar lines.
RVNC: 22.31 (-0.58)
Revance Therapeutics Added to NASDAQ Biotechnology Index
GlobeNewswire - Thu Dec 18, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:^NBI), which will become effective upon market open on Monday, December 22, 2014.
IBB: 363.84 (-0.66), RVNC: 22.31 (-0.58)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 39.96 (-0.50), ZSPH: 42.50 (+1.08), AMRN: 2.34 (-0.05), OPHT: 52.35 (+1.09), AERI: 34.42 (-0.70), ASPX: 100.79 (+0.09), CNCE: 14.83 (+0.26), ICEL: 16.47 (-0.02), GWPH: 113.04 (-0.05), AUXL: 36.47 (-0.06), RTRX: 24.45 (+0.09), RCPT: 166.76 (-3.37), AAVL: 38.93 (-0.42), AKBA: 8.39 (+0.07), EXPR: 17.33 (+0.04), RARE: 66.96 (+2.74), RLYP: 35.39 (-0.54), PETX: 16.15 (+0.01), ENTA: 36.99 (+0.01), RDUS: 41.90 (-0.48), CARA: 12.98 (+0.15), FLML: 15.84 (-0.33), ALIM: 4.92 (-0.09), ANIP: 69.79 (+1.24), ICPT: 280.45 (-8.26), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22), FPRX: 24.07 (-0.85), ZFGN: 39.06 (+0.36), CRIS: 2.88 (+0.09), QLTI: 3.75 (-0.04), PCYC: 256.98 (-0.77), PTX: 7.44 (-0.05), CLDN: 13.59 (-2.77), RIGL: 4.24 (+0.07), HPTX: 45.96 (-0.18), AMPH: 15.08 (-0.13), INO: 10.39 (-0.09), VSAR: 18.31 (-0.81), FMI: 48.71 (-0.96), TBPH: 18.41 (+0.18), XLRN: 33.67 (-0.02), MGNX: 33.73 (-0.05), INSM: 23.12 (-0.10), ONTX: 2.48 (-0.05), ALDR: 25.13 (-0.19), SAGE: 59.50 (-2.56), KITE: 57.56 (-1.43), CGEN: 7.10 (+0.01), FOLD: 11.97 (-0.35), KPTI: 32.24 (-0.60)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 39.96 (-0.50), ZSPH: 42.50 (+1.08), AMRN: 2.34 (-0.05), OPHT: 52.35 (+1.09), AERI: 34.42 (-0.70), ASPX: 100.79 (+0.09), CNCE: 14.83 (+0.26), ICEL: 16.47 (-0.02), GWPH: 113.04 (-0.05), AUXL: 36.47 (-0.06), RTRX: 24.45 (+0.09), RCPT: 166.76 (-3.37), AAVL: 38.93 (-0.42), AKBA: 8.39 (+0.07), EXPR: 17.33 (+0.04), RARE: 66.96 (+2.74), ZGNX: 1.63 (-0.02), RLYP: 35.39 (-0.54), PETX: 16.15 (+0.01), ENTA: 36.99 (+0.01), RDUS: 41.90 (-0.48), CARA: 12.98 (+0.15), FLML: 15.84 (-0.33), ALIM: 4.92 (-0.09), ANIP: 69.79 (+1.24), ICPT: 280.45 (-8.26), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22), NDAQ: 48.84 (+0.12), FPRX: 24.07 (-0.85), CRIS: 2.88 (+0.09), ZFGN: 39.06 (+0.36), QLTI: 3.75 (-0.04), PCYC: 256.98 (-0.77), PTX: 7.44 (-0.05), CLDN: 13.59 (-2.77), RIGL: 4.24 (+0.07), HPTX: 45.96 (-0.18), AMPH: 15.08 (-0.13), INO: 10.39 (-0.09), VSAR: 18.31 (-0.81), FMI: 48.71 (-0.96), TBPH: 18.41 (+0.18), XLRN: 33.67 (-0.02), MGNX: 33.73 (-0.05), INSM: 23.12 (-0.10), ONTX: 2.48 (-0.05), ALDR: 25.13 (-0.19), SAGE: 59.50 (-2.56), KITE: 57.56 (-1.43), CGEN: 7.10 (+0.01), FOLD: 11.97 (-0.35), KPTI: 32.24 (-0.60)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), NKTR: 10.90 (+0.16), AGN: 240.22 (+2.88), IPXL: 49.58 (-0.40), ALDR: 25.13 (-0.19), MRK: 57.69 (+0.03), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 100.43 (+0.13), RVNC: 22.31 (-0.58), CLTX: 0.74 (-0.01), GSK: 46.57 (-0.67), NKTR: 10.90 (+0.16), NVS: 103.45 (-0.62)
Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Thu Nov 20, 6:20PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the 26 Annual Piper Jaffray Healthcare Conference.
RVNC: 22.31 (-0.58)
